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forces e ﬂexion, extension, axial torsion, elongation, short-
ening, compression e in the femoropopliteal segment that
eventually exert their toll on stents deployed therein, notwith-
standing changes due to atherosclerosis itself. This possibly
relates to higher fracture rates in the distal SFA-P1 segments, as
indicated by Davaine et al.,1 and the biomechanical association
with the adductor hiatus (being a relatively ﬁxed part of
that segment), and proximity to the inter-epicondylar line (the
axis for knee ﬂexion), is worth considering.2
Recent meta-analyses cautiously support a primary
stenting approach, rather than as a bail-out option, but
suggest bare metal stent (BMS) fracture rates initially close
to 25%.2 Recent change-over from stainless steel to nitinol
in this area is relevant, reﬂected in the reduced fracture
rates of <5% in the Resilient and Absolute trials, examining
the Lifestent (Bard Peripheral Vascular, USA) and Absolute
stents (Abbott Vascular, USA), and the design proviso that
stents with more ﬂexible cell junctions do better.3
This study examines the signiﬁcance of BMS fracture after
deploying the Lifestent for TASC C/D femoropopliteal lesions,
using a standardised classiﬁcation system, and is thoroughly
detailed. Optimal stent overlaps and numbers deployed are
indicated, which have a bearing on minimising junction frac-
tures and distraction, and the authors have taken care to treat
inﬂow/outﬂow diseases that may have confounded the re-
sults. Under-ballooning of the devices is described; saying that
a 6 mm balloon dilatation of a 7 mm stent causes less damage
than a 7 mm balloon is rather far-fetched. This is particularly
so as the stent should supposedly expand to its designated
size from its shape-memory properties. I cannot see a valid
argument here for “reducing medial damage” e damage
already done by extensive stenting/angioplasty itselfe as this
is precisely why we have aggressive antiplatelet and lipid-
lowering therapy in place. The IFU states stents should be
very slightly oversized; therefore, for example, if a reference
vessel of 6.5 mm is appropriate for a 7 mm stent, a 6 mm
balloon would be inappropriate, as would be coronary anal-
ogies. In general, a 1:1 stent:balloon ratio is more appropriate.
The (seeminglyminor) question that then arises is does under-
ballooning leave residual imperceptible kinks more prone to
fracture, given the stent fracture rate of 17.7% is much higher
than that reported in the Absolute trial? Also, why were biggerDOI of original article: http://dx.doi.org/10.1016/j.ejvs.2013.05.010
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large trees breaking and smaller plants bending is tenuous,
with only 1 mm difference between stents.
Diagnostic angiography e using the rhetorical “time is
tissue” mantra (this is not a cerebrovascular event) e is
obsolescent practice in my view, as most centres should
provide urgent computed tomography angiography (CTA), if
not duplex/magnetic resonance angiography (MRA) (which
provides excellent below-knee vessel images when done
correctly), which reduce contrast and radiation doses.4 In
the 21st century, poor lower limb vascular imaging using
MRA/CTA is largely operator-dependent.
The authors imply BMS fracture is not really a problem
(despite limbs without stent fractures doing better), though
this contradicts recent evidence suggesting fractures relate
directly to loss of patency,3 also indicating that duplex
surveillance alone (generally not undertaken) is possibly
enough e What does one believe now, given the paucity of
robust trials in any case?3
The message perhaps is one should not insert BMS just
because one can (a questionable one noted in the femoral
artery in this series), especially with drug-eluting stents,
drug-coated balloons, and stent-grafts already in current
practice. The authors have no experience with stent-grafts
such as the Viabahn e shown to be clearly superior to
BMS in the Viastar trial, presented recently and currently
awaiting publication e which has extremely low fracture
rates, even in this segment.
In that sense, the article represents a time-warp that the
endovascular community is already moving away from,
perhaps with good reason, but the core message that we
should not worry too much about femoropopliteal stent
fracture is worth pondering over.REFERENCES
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